In addition to agreement for requesting a genetic study in patients with primary hyperparathyroidism (S13), to rule out multiple endocrine neoplasia type 1 (MEN1) [5, 6], there was also consensus to request a genetic study in patients with macroprolactinoma in a first-degree relative, in patients younger than 20 years, and in patients with evidence of pheochromocytoma/paraganglioma (S14, 15 and 16), which are practices not mentioned in guidelines. This evidence concerns the gene MEN1 and primary hyperparathyroidism.